INTRODUCTION
A number of proteolytic enzymes are synthesized as inactive precursors, named proenzymes or zymogens, to protect the cells which produce them. These zymogens must undergo an activation process, usually a limited proteolysis, to change into the active form.
Zymogen activation is a phenomenon which is involved in processes such as complement activation [1] , the transformation of angiotensinogen into angiotensin [2] , proinsulin-insulin conversion [3] , the digestion of proteins in intestin [4] , blood clotting [2, [5] [6] [7] [8] and protyrosinase activation [9] , among others.
These important physiological processes are controlled by the different proteinase inhibitors found in cells and body fluids [10] .
Such inhibitors include the al and a2-macroglobulins involved in the regulation of fibrinolysis [11] ; antithrombin III, involved in blood clotting, which inhibits the activated Factors IX-XII and the action of the thrombin [12] , trypsin inhibitor, which for a number of particular cases of the general model studied. Finally, a kinetic data analysis and a procedure to discriminate among the different mechanisms considered, which are based on the kinetic equations obtained, are suggested. comprises 20% of the protein content of pancreatic juice and whose function is to regulate the cascades of activations of the pancreatic zymogens [4] , etc. Different real examples of systems to which the kinetic study here presented may be applied are shown in detail in Table 1 .
One incentive in inhibitor research is the control of limited proteolysis, as this constitutes a valuable pharmacological tool. Proteinase inhibitors have been proved effective in human therapy [10] [11] [12] [27] [28] [29] . A pathological increase in fibrinolysis, e.g. in leukaemia or in operations involving organs with a high fibrinolysis activator content such as the uterus, prostate or lungs, can be controlled by the use of inhibitors such as 6-aminohexanoic acid, p-aminomethylbenzoic acid or aprotinin. In addition to inhibiting plasmin, they also inhibit trypsin, chymotrypsin and kallikrein, the last being the most important protein responsible for the release of bradykinin from kininogen [12] .
The effect of an inhibitor on the kinetic behaviour of a zymogen activation process has been analysed in a simple, but I The inhibitor acts upon both of the enzymes.
[13-161 [17, 18] [ 16,18-201 [21-24] [12,24,251 [4, 9, 261 Abbreviations used: D-Val-Leu-Lys-Nan, D-valyl-L-leucyl-L-lysine 4 [32, 33] . Nevertheless, the kinetic behaviour of an enzyme system, in which the activation of a zymogen overlaps the inhibition of the involved enzymes, remains to be studied. In the present paper the time course of the product, P, involved in Scheme 1 [eqn. (3) Scheme 2 where
The requirements for the rapid equilibrium conditions in Scheme to prevail and, therefore, for it to become Scheme (2) are as in other studies concerning rapid equilibrium (6, 31, (34) (35) (36) :
The time course of P in Scheme 2 can be easily obtained by inserting the condition (8) (3) and (9) for the accumulation of P in Schemes 1 and 2 respectively correspond to the curves whose form is schematically indicated in Figure 1 . (-;-) K3, K' -too change with respect to Scheme 2 are the steps corresponding to the inhibition reactions, and therefore, we denote in Table 2 each of these particular cases, pointing out the two inhibition reactions only and dividing these by a semicolon (;). We denote by a dash (-), those cases in which either the activating or the activated enzyme is not inhibited. The time course of P for each of the Schemes in Table 2 can be obtained from the corresponding system of differential equations describing its kinetics. However, the same result can be obtained more easily by setting the changes indicated on the third column in Table 2 [PI =-l1 + Y2 A2 t + y1 exp (A1 t) + y2(A2 t)2/2! + y2(A2 t)3/3! + . . . (21) Neglecting the terms which follow the exponential term and taking eqns. (18) , (19) , (C2) and (C3) into account, one obtains eqn. (Cl) in Appendix C. Proceeding in the same way as in this example, the time dependence of P for Schemes 4-6 in Table 1 are derived. The result is summarized in Appendix C. Table 2 are derived. The result is summarized in Appendix C.
Note that the time-course equations for P in Schemes 3-6 (in which only one of the two enzymes is irreversibly inhibited) and in Schemes [7] [8] [9] [10] (in which none of the enzyme species is irreversibly inhibited) are formally identical. In Figure 1 the progress curves ofP corresponding to these schemes are schematically plotted. The progress curve of P at the steady state in Schemes 3-6 becomes a straight line with slope a (i.e., the steadystate initial rate) and an intercept with the [P]-axis a. The intercept of these straight lines with the t-axis, i.e. the induction period, is given by:
The progress curves of P for Schemes 7-10 are parabolic from t = 0, as indicated by eqn. (C20), and the rate of product formation never reaches a constant value but, on the contrary, increases linearly with t; i.e., in these Schemes the steady state is not strictly reached.
In Figure 2 we show the experimental product accumulation curves as well as the corresponding ones fitted by linear regression to eqn. (C20), for the plasminogen activation reactions with t-PA in the absence (Scheme 10, curve i) and presence (Scheme 7, curve ii) of a reversible inhibitor of both the activating and the activated enzyme, 6-aminohexanoic acid. From linear regression of the above experimental curves, the values of the parameter A were 0.9317x10-2 and 3.4214x10#2,tM min-2 respectively.
Note the agreement between the experimental data and the expected parabolic behaviour for the Schemes 10 and 7. The activation of plasminogen catalysed either by urokinase or t-PA (according to Scheme 10) situation in which not all the reversible steps, or none, are in rapid-equilibrium conditions. Data-fitting must be made by nonlinear regression [37, 38] . We have limited the discrimination to Schemes 2-10. To discriminate among other possible schemes, which are particular cases of Scheme 1, including itself, we followed analogous procedures based on the form of the time-course equations of P and in the form of their corresponding progress curves.
Once we know that the scheme is one of the Schemes 2-10, the following procedure, based on the form of the time-dependence equation of P and on the corresponding progress curves, is suggested.
(1) A concentration of P which remains constant at the steady state is only compatible with Scheme 2.
(2) A behaviour at the steady state, which supposes that the progress curve becomes a straight line with positive slope not passing through the origin, is only compatible with Schemes 3-6. Hence, to discriminate among these four Schemes, we proceed as follows.
( Kinetic data analysis of Schemes [2] [3] [4] [5] [6] [7] [8] [9] [10] To evaluate the equilibrium and rate constants involved in Schemes 2-10, we begin by classifying these schemes into the following four groups; Group (a) includes Scheme 10, i.e., the only one in Table 1 The kinetic data analysis used for any of the above mechanisms depends on the group in which it is included. Below we indicate the procedure suggested for each case.
The Scheme belonging to Group (a) In this case the Scheme is 10. We proceed as follows. In an assay where there are only the activated enzyme, Ea, and the substrate, S, the Scheme is simplified to Scheme 2b, which is a simple Michaelis-Menten mechanism, and therefore the constants KI andkV2 are easy to obtain from the steady-state rate,a. 
R. Var6n and others
The Scheme belonging to Group (b) An assay without inhibitor must be carried out, and then we proceed in the same way as for Scheme 10 to determine the constants, K1, k12, K'1 and k' 2. The rate constants corresponding to the inhibitions are evaluated, taking into account the procedure for proteinase inhibitors [32] .
The Scheme belonging to Group (c)
The constants K1, k+2, K1 and k+2 and those corresponding to the irreversible inhibition step (K' and k' in Scheme 3 and K3 and kI in Scheme 4) are determined as described previously. To determine the equilibrium rate of the reversible inhibition (K3 in Scheme 3 and K3 in Scheme 4), the progress curve of [P] of the global process and the corresponding experimental steady-state rate and induction period must be used together with the corresponding theoretical equation for these parameters (eqns. C2 and C5). Hence, taking into account eqns. (C2), (C5), (B8) and (C8) for Scheme 3 and eqns. (C2), (C5), (B8) and (Cl1) for Scheme 4, a plot of T (see Appendix C)/a versus [1] (3 + 
Derivation of the time course of the product P, taking into account rapid equilibrium conditions
If we insert condition (11) 
where: the product concentration, [P] , is given by eqn. (9) in the main paper.
To obtain the parameters involved in this equation, we must take into account the following: if in eqn. (4) we consider condition (8) and divide both the numerator and denominator by k1 k+ k3 k+3, we obtain: er = +2 k+2 K3 K3 [E] 
